Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382811314> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W4382811314 endingPage "S126" @default.
- W4382811314 startingPage "S126" @default.
- W4382811314 abstract "Elderly patients, defined by the World Health Organization as individuals over the age of 65, represent a heterogeneous group with different biological and functional characteristics that require personalized anticancer treatments. An appropriate balance between the potential benefits of treatment and the side effects represents the crucial point for managing elderly patients with pancreatic cancer. The study of mFolfirinox excludes elderly patients, but in our setting, access to gemcitabine with nab-paclitaxel is limited due to its high cost. The field of geriatric oncology will expand in the coming years, and the clinical management of elderly patients affected by pancreatic cancer will become an important public health problem. The medical records of the Oncology Section of Hospital Italiano Buenos Aires were retrospectively analyzed from 2020 to 2022 for patients with advanced pancreatic cancer, focusing on the oldest patients. Clinical characteristics and treatments were evaluated, and clinical outcomes were compared with FOLFIRINOX among patients over and under 65 years of age. 152 patients with pancreatic cancer received chemotherapy treatment, with 47% (72) considered elderly. Of these, 36% (26) were given mFOLFIRINOX because they did not have access to other chemotherapy regimens, with a median age of 71 years (IQR 67-76) and all with PS 0-1. 81% required dose reduction due to toxicity compared to 70% of those under 65 years of age. 57% presented with grade 3-4 toxicities, while 43% of those under 65 years of age presented with these grades of toxicity. During one-year follow-up, 65% of elderly patients died, while 52% of those under 65 years of age were still alive. The median progression-free survival in patients over 65 years of age was 7.8 months compared to 9.37 months in those under 65 years of age. Regarding overall survival, older patients had a survival rate of 11.5 months compared to 14 months in those under 65 years of age. mFOLFIRINOX proved to be a regimen with a significant rate of grade 3-4 toxicity in patients over 65 years of age. Most patients required dose adjustments, and the median progression-free survival and overall survival were lower than clinical studies. Considering these results, this polychemotherapy scheme should be reserved for young or very selected patients." @default.
- W4382811314 created "2023-07-02" @default.
- W4382811314 creator A5005297871 @default.
- W4382811314 creator A5032252100 @default.
- W4382811314 creator A5039055629 @default.
- W4382811314 date "2023-06-01" @default.
- W4382811314 modified "2023-09-23" @default.
- W4382811314 title "P-315 Chemotherapy treatment with mFOLFIRINOX in elderly patients with advanced pancreatic cancer" @default.
- W4382811314 doi "https://doi.org/10.1016/j.annonc.2023.04.371" @default.
- W4382811314 hasPublicationYear "2023" @default.
- W4382811314 type Work @default.
- W4382811314 citedByCount "0" @default.
- W4382811314 crossrefType "journal-article" @default.
- W4382811314 hasAuthorship W4382811314A5005297871 @default.
- W4382811314 hasAuthorship W4382811314A5032252100 @default.
- W4382811314 hasAuthorship W4382811314A5039055629 @default.
- W4382811314 hasBestOaLocation W43828113141 @default.
- W4382811314 hasConcept C121608353 @default.
- W4382811314 hasConcept C126322002 @default.
- W4382811314 hasConcept C143998085 @default.
- W4382811314 hasConcept C195910791 @default.
- W4382811314 hasConcept C2776694085 @default.
- W4382811314 hasConcept C2777148230 @default.
- W4382811314 hasConcept C2777319248 @default.
- W4382811314 hasConcept C2780210213 @default.
- W4382811314 hasConcept C2780258809 @default.
- W4382811314 hasConcept C2780259306 @default.
- W4382811314 hasConcept C526805850 @default.
- W4382811314 hasConcept C71924100 @default.
- W4382811314 hasConceptScore W4382811314C121608353 @default.
- W4382811314 hasConceptScore W4382811314C126322002 @default.
- W4382811314 hasConceptScore W4382811314C143998085 @default.
- W4382811314 hasConceptScore W4382811314C195910791 @default.
- W4382811314 hasConceptScore W4382811314C2776694085 @default.
- W4382811314 hasConceptScore W4382811314C2777148230 @default.
- W4382811314 hasConceptScore W4382811314C2777319248 @default.
- W4382811314 hasConceptScore W4382811314C2780210213 @default.
- W4382811314 hasConceptScore W4382811314C2780258809 @default.
- W4382811314 hasConceptScore W4382811314C2780259306 @default.
- W4382811314 hasConceptScore W4382811314C526805850 @default.
- W4382811314 hasConceptScore W4382811314C71924100 @default.
- W4382811314 hasLocation W43828113141 @default.
- W4382811314 hasOpenAccess W4382811314 @default.
- W4382811314 hasPrimaryLocation W43828113141 @default.
- W4382811314 hasRelatedWork W2012954058 @default.
- W4382811314 hasRelatedWork W2138640290 @default.
- W4382811314 hasRelatedWork W2376347278 @default.
- W4382811314 hasRelatedWork W2599910524 @default.
- W4382811314 hasRelatedWork W2721585150 @default.
- W4382811314 hasRelatedWork W2910998150 @default.
- W4382811314 hasRelatedWork W3008650849 @default.
- W4382811314 hasRelatedWork W3046481916 @default.
- W4382811314 hasRelatedWork W3154040450 @default.
- W4382811314 hasRelatedWork W3196960728 @default.
- W4382811314 hasVolume "34" @default.
- W4382811314 isParatext "false" @default.
- W4382811314 isRetracted "false" @default.
- W4382811314 workType "article" @default.